LifeSci Venture Partners’ Paul Yook Moderates “What’s Hot in Biopharma Investing?” Panel at MedCity INVEST Conference


NEW YORK, May 30, 2017 (GLOBE NEWSWIRE) -- On May 18, LifeSci Advisors’ Paul Yook, General Partner, LifeSci Venture Partners, moderated the opening panel at MedCity INVEST, a healthcare investing conference held this year in Chicago, IL.

Led by Yook, the “What’s Hot in Biopharma Investing?” panel included Jack Gilbert, Co-Founder and Scientific Advisor, Gusto Global; Director, Microbiome Center, University of Chicago, Ed Mathers, Partner, NEA and Ilan Zipkin, Ph.D., Senior Investment Director, Takeda Ventures, Inc. The discussion touched on topics ranging from trends in the industry to advice on pitching VC investors.

The two-day INVEST Conference drew nearly 400 business, healthcare and technology executives and investors from around the country to network and learn about trends and opportunities in the industry.

“It’s important to hear perspectives from both the VC and laboratory side on where the industry is going,” said Paul Yook. “The INVEST audience wants to know what’s coming next in the biopharma industry and discussions like this are crucial for staying ahead of the curve.”  

Yook established and manages LifeSci Venture Partners, a newly launched healthcare venture capital fund affiliated with LifeSci Partners, and LifeSci Index Partners, an SEC-registered investment advisor and index provider to the BioShares exchange traded funds. Prior to joining LifeSci in June 2014, Yook worked as a healthcare hedge fund portfolio manager and equity research analyst at Galleon Management. He began his Wall Street career in healthcare investment banking at UBS Securities and at Goldman, Sachs & Co. where he was involved in numerous IPOs, secondary offerings and M&A transactions for healthcare companies ranging from small, emerging biotechnology companies to large, multinational pharmaceutical companies. He earned a B.S.E. in Economics from the Wharton School and a B.A. in Biochemistry from the College of Arts and Sciences at the University of Pennsylvania.

MedCity INVEST is presented by MedCity News, producer of unique innovation-focused events across the healthcare ecosystem, and MHIN (Mid-America Healthcare Investors Network), a nonprofit organization composed of more than 40 venture capital firms. The INVEST conference is the premier national healthcare investing conference based in the Midwest. For well over a decade, INVEST has united active investors with corporate business development executives to syndicate investment opportunities with promising start-ups from the biopharmaceutical, diagnostics, medical devices, digital health/health IT and health services sectors.

About LifeSci Advisors:

LifeSci Advisors, LLC (www.lifesciadvisors.com) is a unique investor relations consultancy founded to provide companies in the life sciences a comprehensive solution to investor communications and outreach. With a local presence in New York, Boston, Chicago, Philadelphia, London, Geneva and Tel Aviv, the firm provides the highest quality service for its clients through its deep sector specialization. Our roster of PhDs enables us to better understand our clients' R&D, regulatory, and commercial strategy, and our team of financial services, investor relations, and public relations specialists help our clients effectively communicate to the marketplace. This combination of life sciences, financial services, and investor relations competencies allows us to provide a valuable and unique service offering to our clients.

About LifeSci Partners:

LifeSci Partners (www.lifescipartners.com) is the leading provider of comprehensive consulting services in the areas of investor relations, corporate communications, public relations and capital markets advisory.  Combining deep domain expertise in the life sciences and decades of experience in capital markets and public relations, we deliver unparalleled services to life sciences companies globally.  LifeSci Partners has a physical presence in New York, Chicago, London, Geneva and Israel.


            

Contact Data